APRIL 2017 Deal Watch Review now published.
Alan Warrander has over 25 years wide-ranging experience in the Pharmaceutical Industry having worked both in Pharma companies and as a Consultant.
Until the end of 2007, Alan was Senior Vice President, Life Sciences at Wood Mackenzie, the global consultancy firm where he provided consultancy advice and expert scientific opinion to Pharma, Biotech companies, Finance groups and Law firms primarily in the areas of Partnering, Due Diligence and Strategic Planning. Alan was also responsible for the production of a number of Expert Reports on a range of companies in support of potential AIM flotations.
Prior to joining Wood Mackenzie in mid-2005, Alan was a Director of Global Licensing with AstraZeneca where he covered all aspects of partnering (Evaluation, Due Diligence and Transaction Management) for the Oncology and Infection Therapeutic Areas. Before moving to Licensing in 1998, for a considerable number of years, Alan led a Drug Metabolism/Pharmacokinetics Unit at ICI/Zeneca Pharmaceuticals with previous experience in the Drug Metabolism department of Hoechst and as head of the Drug Metabolism section at Sterling-Winthrop.
His academic background is in Xenobiotic Metabolism, with a PhD from Birmingham University and a BSc in Chemistry and Biochemistry from St Andrews. He is a recognised conference speaker having being invited to present on various aspects of Partnering and Due Diligence.